On November 18, Recursion Pharmaceuticals, Inc. rose 5.51% in Regular Trading, trading at $2.8823 per share, with turnover of $5.8009 million.
The move followed the company’s announcement that it aligned with the US Food and Drug Administration on the phase 3 trial design for REC-4881 in familial adenomatous polyposis, providing a clearer regulatory path for a late-stage study.
According to the company update, the study is expected to enroll about 200 patients aged 18 or older who have undergone colectomy or proctocolectomy, and will evaluate REC-4881 at a 4 milligram dose, with the dosing schedule to be determined using data from an ongoing trial. The phase 3 trial remains on track to start in the second half of 2027. Earlier updated TUPELO data had shown deep and durable reductions in polyp burden with a relatively clean safety profile, while the company’s latest quarterly revenue of $18.552 million exceeded the $14.783 million consensus estimate.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments